Regeneron Pharmaceuticals is set to acquire 23andMe, a genetic testing company that filed for bankruptcy in March, for $256 million. The deal will see Regeneron take control of the sensitive genetic information of millions of 23andMe customers.
Regeneron’s acquisition of 23andMe comes after the biotechnology company developed new drugs using DNA research and identified an opportunity to expand its research capabilities. Under the deal, Regeneron will continue to offer consumer DNA testing services, while also strengthening its research into new treatments for serious diseases.
The acquisition is expected to close in the third quarter of 2025, pending approval by a bankruptcy court and regulators. To ensure customer data protection, Regeneron has stated that it will comply with 23andMe’s consumer privacy policies and laws governing the treatment of customer data.
Regeneron’s co-founder, president, and chief scientific officer Dr. George D. Yancopoulos, said that the acquisition would allow 23andMe to deliver on its mission to help customers improve their personal health, while furthering Regeneron’s efforts to use large-scale genetics research to prevent illness overall.
The deal also includes job offers for all employees in the business units being acquired, according to 23andMe’s chair and member of the special committee of the board. California’s attorney general has expressed support for the acquisition, stating that it will help protect consumers’ rights and ensure the company’s commitment to data protection.
Source: https://www.nytimes.com/2025/05/19/business/regeneron-pharmaceuticals-23andme-data.html